Keeping Up With The CGRPs: Alder Gains Momentum In A Tight Race
This article was originally published in The Pink Sheet Daily
Alder released positive Phase IIb data testing its intravenous CGRP antibody March 28 as the race to bring a first-in-class product to market for the prevention of migraine intensifies.
You may also be interested in...
US FDA will be cautious about development of a COVID-19 vaccine for children, Commissioner Hahn says at the Financial Times US Pharma And Biotech Summit.
The US FDA appears to have concerns about the device used to administer the vaccine.
Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.